Statistical Analyses All statistical analyses were performed using SAS versions 9.3 or 9.4 (SAS Institute, Cary, NC, USA)
GH/IGF-1 axis modulation: Preclinical research assessing how the blend influences growth hormone and insulin-like growth factor 1 (IGF-1) patterns in controlled endocrine models, without implying any therapeutic or performance outcomes
Through its indirect endocrine effect, it prevents PCOS, amenorrhea and other problems related to the female reproductive cycle
Notably, some might experience an increased heart rate, higher blood pressure, insomnia, or dry mouth
To measure lifetime use, Gallup asked: Have you ever taken weight loss medications such as semaglutide (brand names Ozempic and Wegovy), liraglutide (brand name Saxenda) or tirzepatide (brand names Mounjaro and Zepbound)? To measure current individual use (if yes to the first question), Gallup then asked: Are you currently taking weight loss medications such as semaglutide (brand names Ozempic and Wegovy), liraglutide (brand name Saxenda) or tirzepatide (brand names Mounjaro and Zepbound)? The Food and Drug Administration (FDA) approved the Novo Nordisk drug Wegovy (semaglutide) for weight loss in 2021
Ozempic and Wegovy were initially approved by the FDA as diabetes treatments that slow digestion, staving off feelings of hunger
